BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER
Clinical trials for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER explained in plain language.
Never miss a new study
Get alerted when new BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER trials appear
Sign up with your email to follow new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…
Matched conditions: BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…
Matched conditions: BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC